CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
受者来源异基因 CAR-T 细胞治疗后儿科患者因特发性肺炎综合征导致的呼吸衰竭
英文原题：Respiratory Failure Due to Idiopathic Pneumonia Syndrome in a Pediatric Patient After Recipient-derived Allogeneic Chimeric Antigen Receptor T-Cell Therapy.
查看英文原题
Respiratory Failure Due to Idiopathic Pneumonia Syndrome in a Pediatric Patient After Recipient-derived Allogeneic Chimeric Antigen Receptor T-Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
特发性肺炎综合征（IPS）是造血细胞移植后一种危及生命的并发症，但在嵌合抗原受体（CAR）T细胞治疗后尚未得到明确描述。我们描述了一名儿童，因造血细胞移植后复发性急性淋巴细胞白血病接受tisagenlecleucel治疗后发生IPS，经皮质类固醇和依那西普治疗后获得显著改善。我们讨论了细胞因子信号在IPS中的意义以及异基因CAR-T 细胞的免疫学考量。我们预计，随着异基因CAR-T 细胞在更多样化的环境中、使用更多错配供者，IPS和其他异基因现象的发生率将被更频繁地观察到。
展开英文摘要原文
Idiopathic pneumonia syndrome (IPS) is a life-threatening complication of hematopoietic cell transplantation, but it is not clearly described following chimeric antigen receptor (CAR) T-cell therapy.
We describe a child who developed IPS after receiving tisagenlecleucel for post-hematopoietic cell transplantation relapsed acute lymphoblastic leukemia and had a remarkable improvement after treatment with corticosteroids and etanercept.
We discuss the implications of cytokine signaling in IPS and immunologic considerations of allogeneic CAR T cells.
We anticipate that the incidence of IPS and other allogeneic phenomena will be observed more often as allogeneic CAR T cells are employed in more varied settings with more mismatched donors.
论文信息
- 作者
- Zipper R、Loeb DM、Lee MA、Oliver-Krasinski J、Liszewski MC、Fraint E
- 第一作者单位
- Departments of Pediatrics.
- 通讯作者单位
- Division of Pediatric Hematology, Oncology, and Cellular Therapy, Children's Hospital at Montefiore.
- 期刊
- Journal of pediatric hematology/oncology2023 Aug 1
- 原文标识
- PubMed 37314946 · DOI 10.1097/MPH.0000000000002693